Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

Clinical trial NCT04908956 · TERMINATED

Trial details

NCT number: NCT04908956
Sponsor: ETOP IBCSG Partners Foundation
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC Stage IV EGFR Gene Mutation

Start date: 2022-08-04
Primary completion: 2023-10-31
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.